Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 1 Sociodemographic and clinical characteristics of study participants at baseline (n = 134)

From: Pulmonary restriction predicts long-term pulmonary impairment in people with HIV and tuberculosis

Characteristic

n (%) or median (IQR)

Age

36 (31–43)

Female

57 (43)

Black African race

134 (100)

BMI

19.1 (17.9–21.8)

Current smoker

21 (16)

Ever smoker

53 (40)

Pack-years of cigarettes

2.8 (1.2–7.5)

Chronic lung disease

0 (0)

History of mine work

2 (1)

HbA1c

6.1 (5.8–6.4)

CD4 cell count (cells/μl)

110 (49–194)

HIV viral load (copies/ml)

146,742 (54,194–494,851)

FEV1% predicted

79 (66–89)

FVC % predicted

85 (73–95)

FEV1/FVC ratio

79 (73–85)

Time from TB treatment to ART initiation (days)

24 (15–42)

  1. ART antiretroviral therapy, BMI body mass index, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, HbA1c hemoglobin A1c, IQR interquartile range
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us